Alcobra Ltd (ADHD.O)

ADHD.O on Consolidated Issue listed on NASDAQ Global Market

3.63USD
24 Oct 2014
Price Change (% chg)

$-0.57 (-13.57%)
Prev Close
$4.20
Open
$4.12
Day's High
$4.12
Day's Low
$3.45
Volume
1,428,993
Avg. Vol
479,171
52-wk High
$25.44
52-wk Low
$3.45

ADHD.O

Chart for ADHD.O

About

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and... (more)

Overall

Beta: --
Market Cap (Mil.): $49.50
Shares Outstanding (Mil.): 13.64
Dividend: --
Yield (%): --

Financials

  ADHD.O Industry Sector
P/E (TTM): -- 161.00 34.06
EPS (TTM): -1.87 -- --
ROI: -85.87 -1.64 17.45
ROE: -85.87 -6.68 18.26
Search Stocks

Alcobra ADHD drug meets goals, after data excluded; stock tanks

- Alcobra Ltd lost more than half its market value after it said its drug to treat adult attention deficit disorder met the main goals of a late-stage trial - but only after excluding data from patients who reacted positively to a placebo.

06 Oct 2014

UPDATE 2-Alcobra ADHD drug meets goals, after data excluded; stock tanks

(Adds conference call details; CEO , analyst comments; updates shares)

06 Oct 2014

US STOCKS-Small biotech stocks plummet in premarket

NEW YORK, Oct 6 - Sunesis Pharmaceuticals and Alcobra Ltd were both sharply lower in premarket trading on Monday, with both names tumbling on heavy volume after reporting the results of late-stage drug trials.

06 Oct 2014

Alcobra's ADHD drug meets goals in late-stage study

Oct 6 - Alcobra Ltd said its drug to treat attention deficit disorder met the main goals of a late-stage trial, reducing the symptoms of the condition better than a sugar pill.

06 Oct 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Zacks Investment Research Inc.
$12.00
Provider: Zacks Investment Research Inc.
$12.00
Provider: Zacks Investment Research Inc.
$12.00
Provider: Zacks Investment Research Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks